Primary Site >> Pancreatic Cancer
Gene >> IL2RA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Cytotoxic activity and phenotypic characteristics of lymphocyte subsets after therapy of cancer patients with interleukin-2. PMID: 1878892 |
Ref: Autologous tumour-specific cytotoxic T-cell clone established from tumour-infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2(rIL2): activation by autologous tumour cell alone. PMID: 8507542 Ref: The expression and biological activity of IL-2 receptor on a human pancreas cancer cell line. PMID: 8507543 |
Ref: Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC. PMID: 8528743 |
Ref: Prognostic significance of soluble interleukin-2 receptor-alpha in adenocarcinoma of the pancreas. PMID: 10025881 Ref: [Prognostic value of molecular biologogy and immunologic parameters in human pancreatic carcinoma]. PMID: 14518215 |
Ref: MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment. PMID: 12820727 |
Ref: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. PMID: 12193750 |
Ref: Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. PMID: 15185013 Ref: Can IL-2R alpha be a valuable marker along with CA 19-9 in the diagnosis of chronic pancreatitis and pancreatic cancer? PMID: 15503821 |
Ref: CD25+ CD4+ regulatory T-cells in cancer. PMID: 16106066 |
Ref: Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. PMID: 16799337 Ref: Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice. PMID: 16952047 Ref: Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. PMID: 17079944 |
Ref: Systemic immune dysfunction in pancreatic cancer patients. PMID: 17235586 Ref: Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. PMID: 17652277 |
Ref: Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. PMID: 20357913 |
Ref: Enhanced inhibition of tumor growth with depletion of CD25 regulatory cells and intratumoral immunization with tumor RNA-pulsed dendritic cells in a C57BL/6 pancreatic tumor model. PMID: 19550282 Ref: Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer. PMID: 19578774 |
Ref: An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. PMID: 20473889 Ref: Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. PMID: 21551368 Ref: Pancreatic cancer alters human CD4+ T lymphocyte function: a piece in the immune evasion puzzle. PMID: 21792088 |
Ref: Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. PMID: 22158072 Ref: Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's Toxin. PMID: 23193416 |
Ref: GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. PMID: 23200667 |
Ref: Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer. PMID: 23443635 Ref: Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer. PMID: 23860726 Ref: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. PMID: 25008236 |
Ref: Innate Response to Human Cancer Cells with or without IL-2 Receptor Common gamma-Chain Function in NOD Background Mice Lacking Adaptive Immunity. PMID: 26170385 Ref: [Pathophysiology and Assessment of IgG4-Related Disease--Focus on Autoimmune Pancreatitis]. PMID: 26897857 |
Ref: Effects of active bufadienolide compounds on human cancer cells and CD4+CD25+Foxp3+ regulatory T cells in mitogen-activated human peripheral blood mononuclear cells. PMID: 27431260 |
Ref: Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. PMID: 28614908 Ref: Gemcitabine-Induced TIMP1 Attenuates Therapy Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. PMID: 28765154 |
Ref: CD25 and TGF-beta blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. PMID: 30359281 |